AtheroNova Inc.

Equities

AHROQ

US0474383041

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-26.67%

2016	AtheroNova Operations, Inc. Bankruptcy Case Dismissed	CI
2015	First Motion for Exclusivity Period Extension Approved For AtheroNova Operations, Inc.	CI

AtheroNova Inc. Announces Earnings Results for the Year-Ended December 31, 2013

March 06, 2014 at 08:30 am EST

AtheroNova Inc. announced earnings results for the year-ended December 31, 2013. For the year, the company reported net loss attributable to holders of common stock was $7.81 million or $0.20 basic and diluted loss per share against $2.64 million or $0.09 basic and diluted loss per share a year ago.

Latest news about AtheroNova Inc.

AtheroNova Operations, Inc. Bankruptcy Case Dismissed	16-05-18	CI
First Motion for Exclusivity Period Extension Approved For AtheroNova Operations, Inc.	15-08-14	CI
First Motion for Exclusivity Period Extension Filed by AtheroNova Operations, Inc.	15-06-24	CI
Reorganization Plan and Disclosure Statement Filed by AtheroNova Operations, Inc.	15-06-22	CI
AtheroNova Inc. will Change its Ticker to AHRO.Q from AHRO	15-03-04	CI
AtheroNova To Sell Assets Under Chapter 11	15-03-03	CI
Motion for Joint Administration Approved for AtheroNova Operations, Inc.	15-03-02	CI
AtheroNova Operations, Inc. Filed for Bankruptcy	15-03-01	CI
Motion for Joint Administration Filed by AtheroNova Operations, Inc.	15-03-01	CI
Certain shares of AtheroNova Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 26-JAN-2015.	15-01-26	CI
Certain shares of AtheroNova Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 26-JAN-2015.	15-01-25	CI
AtheroNova Inc. Announces Resignation of Chaim Davis from the Board of Directors	14-12-09	CI
AtheroNova Inc. Announces Resignation of Gary Freeman as a Member of Board of Directors and Chair of Audit Committee	14-11-20	CI
AtheroNova Inc. announced that it has received $0.5 million in funding from W-Net Fund I, L.P.	14-09-11	CI
Atheronova Inc. Accomplishes First Dosing of Subjects for its Phase 1B Clinical Trial with AHRO-001	14-07-30	CI
AtheroNova Inc. Reports Earnings Results for the First Quarter Ended March 31, 2014	14-05-19	CI
Randolph M. Johnson Joins AtheroNova Inc. as Chief Operating Officer	14-04-08	CI
AtheroNova Inc. Auditor Raises 'Going Concern' Doubt	14-03-18	CI
AtheroNova Mulls Acquisitions	14-03-18	CI
AtheroNova Inc. Announces Earnings Results for the Year-Ended December 31, 2013	14-03-06	CI
AtheroNova Inc. Announces Preliminary Positive Phase 1 Clinical Data from Drug AHRO-001	14-02-27	CI
AtheroNova Inc. announced that it has received $1.91 million in funding from Knoll Capital Management.	14-02-11	CI
AtheroNova Inc. announced that it expects to receive $1.40 million in funding from Knoll Capital Management and other investors.	14-01-12	CI
AtheroNova Completes Enrollment in Phase 1 Clinical Trial of AHRO-001	13-12-05	CI
AtheroNova Inc. Appoints Dr. Erik Stroes to its Clinical Advisory Board	13-10-15	CI

Chart AtheroNova Inc.

Duration

Period

More charts

Company Profile

AtheroNova Inc. is a clinical-stage biopharmaceutical company. The Company through its subsidiary, AtheroNova Operations, Inc., is focused on the research and development of compounds to regress atherosclerotic plaque and improve lipid profiles in humans. The Company develops various applications for its compounds to be used for the treatment of atherosclerosis. The Company's development products include AHRO-001 and AHRO-002. The Company's pipeline candidates include applications for the treatment of localized reduction of subcutaneous fat deposits through transdermal application, obesity, hypertension, diabetes and Peripheral Artery Disease (PAD). The Company's lead compound is AHRO-001. Through the process of reverse cholesterol transport, the compound is designed to dissolve plaque within the walls of the arteries and removes it from the body through natural metabolic processes. AHRO-001 and AHRO-002 are orally administered compounds.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ATHERONOVA INC.	-26.67%	9.69K
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+49.56%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research